Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Cellectis Inc. < Previous 1 2 Next > Cellectis to Present Pre-Clinical Data on HSPC Gene Therapy Program and Comprehensive Analysis of TALE-BE at the ESGCT 30th Annual Congress October 24, 2023 From Cellectis Inc. Via GlobeNewswire Tickers CLLS Cellectis and Imagine Institute Publish A Proof-Of-Concept Study of a Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase Δ Syndrome Type 1 (APDS1) October 12, 2023 From Cellectis Inc. Via GlobeNewswire Tickers CLLS Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting September 27, 2023 From Cellectis Inc. Via GlobeNewswire Tickers CLLS Cellectis Provides Full Report for Second Quarter 2023 Financial Results August 07, 2023 From Cellectis Inc. Via GlobeNewswire Tickers CLLS Cellectis Provides Business Updates and Preliminary Financial Results for Second Quarter 2023 August 03, 2023 From Cellectis Inc. Via GlobeNewswire Tickers CLLS Cellectis to Report Second Quarter 2023 Financial Results on August 3, 2023 July 27, 2023 From Cellectis Inc. Via GlobeNewswire Tickers CLLS Cellectis Appoints Dr. Cécile Chartier, Ph.D. to its Board of Directors July 12, 2023 From Cellectis Inc. Via GlobeNewswire Tickers CLLS Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 27, 2023 June 28, 2023 From Cellectis Inc. Via GlobeNewswire Tickers CLLS Cellectis Presents Updated Clinical and Translational Data on BALLI-01 at the European Hematology Association (EHA) 2023 June 09, 2023 From Cellectis Inc. Via GlobeNewswire Tickers CLLS Cellectis Showcased Preclinical Data at an Oral Presentation and Two Poster Presentations at the 29th International Society for Cell & Gene Therapy (ISCT 2023) Annual Event June 05, 2023 From Cellectis Inc. Via GlobeNewswire Tickers CLLS Cellectis Publishes an Article in Cancer Immunology Research Demonstrating Preclinical Evidence of UCART20x22 Product Candidate to Target a Broad Spectrum of Patients with B-cell Malignancies May 31, 2023 From Cellectis Inc. Via GlobeNewswire Tickers CLLS Cellectis Presents Clinical Data on AMELI-01 and Preclinical Data on Multiplex Engineering for Superior Generation of CAR T-cells at ASGCT 2023 May 17, 2023 From Cellectis Inc. Via GlobeNewswire Tickers CLLS Cellectis Publishes Article in Frontiers in Immunology Unveiling Pre-Clinical Data on a Novel Treatment Paradigm for Successful CAR T Immunotherapy Against Stroma-rich Solid Tumors May 12, 2023 From Cellectis Inc. Via GlobeNewswire Tickers CLLS Cellectis Announces Poster Presentation on BALLI-01 at the European Hematology Association (EHA) 2023 May 11, 2023 From Cellectis Inc. Via GlobeNewswire Tickers CLLS Cellectis Provides Business Update and Reports Financial Results for First Quarter 2023 May 04, 2023 From Cellectis Inc. Via GlobeNewswire Tickers CLLS Cellectis Announces Oral Presentation on AMELI-01 and Poster Presentation on Multiplex Engineering for Superior Generation of CAR T-cells at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting May 02, 2023 From Cellectis Inc. Via GlobeNewswire Tickers CLLS Cellectis to Report First Quarter 2023 Financial Results on May 4, 2023 April 27, 2023 From Cellectis Inc. Via GlobeNewswire Tickers CLLS Cellectis Implements CLLS52 for the First Time in the Clinic with Sanofi’s Alemtuzumab April 24, 2023 From Cellectis Inc. Via GlobeNewswire Tickers CLLS Cellectis Presents Preclinical Data on TALEN®-edited MUC1 CAR T-cells to Enhance Efficacy in Targeting Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting April 17, 2023 From Cellectis Inc. Via GlobeNewswire Tickers CLLS Cellectis Announces Dosing of the First Patient in Europe with its In-house Manufactured Product Candidate UCART22 April 11, 2023 From Cellectis Inc. Via GlobeNewswire Tickers CLLS Cellectis enters into warrant agreement with the European Investment Bank related to credit facility agreement and announces the drawdown of the first tranche of €20 million April 04, 2023 From Cellectis Inc. Via GlobeNewswire Tickers CLLS Cellectis Announces Poster Presentation on TALEN®-edited MUC1 CAR T-cells Targeting Triple Negative Breast Cancer at the American Association of Cancer Research (AACR) Annual Meeting March 14, 2023 From Cellectis Inc. Via GlobeNewswire Tickers CLLS Cellectis Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results March 08, 2023 From Cellectis Inc. Via GlobeNewswire Tickers CLLS Calyxt, Inc. Reports its Fourth Quarter 2022 Financial Results and Provides Corporate Update March 06, 2023 From Cellectis Inc. Via GlobeNewswire Tickers CLLS CLXT Cellectis to Report Fourth Quarter and Year-End 2022 Financial Results on March 8, 2023 March 01, 2023 From Cellectis Inc. Via GlobeNewswire Tickers CLLS Cellectis Announces Closing of Global Offering and Exercise of Underwriters’ Option to Purchase Additional Shares February 07, 2023 From Cellectis Inc. Via GlobeNewswire Tickers CLLS Cellectis Supplements the Announcement of the Pricing of Follow-On Offering with Allocation of Share Capital Information February 03, 2023 From Cellectis Inc. Via GlobeNewswire Tickers CLLS Cellectis Announces Pricing of Follow-On Offering February 03, 2023 From Cellectis Inc. Via GlobeNewswire Tickers CLLS Cellectis Announces Launch of Follow-On Offering February 02, 2023 From Cellectis Inc. Via GlobeNewswire Tickers CLLS Cellectis Amends $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics January 20, 2023 From Cellectis Inc. Via GlobeNewswire Tickers CLLS < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
